299 related articles for article (PubMed ID: 21393488)
21. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia.
Perreault S; Levinton C; Le Lorier J
Can J Clin Pharmacol; 2000; 7(3):144-54. PubMed ID: 11044760
[TBL] [Abstract][Full Text] [Related]
23. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
24. [Statins (HMG-CoA reductase inhibitors)].
Gotoda T
Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
[TBL] [Abstract][Full Text] [Related]
25. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
26. Dyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?
Scarpioni R; Ricardi M; Melfa L; Cristinelli L
Cardiovasc Ther; 2010 Dec; 28(6):361-8. PubMed ID: 20553296
[TBL] [Abstract][Full Text] [Related]
27. [Hyperlipidemia in the elderly].
Kawano M
Nihon Rinsho; 2002 May; 60(5):1017-23. PubMed ID: 12029980
[TBL] [Abstract][Full Text] [Related]
28. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Navaneethan SD; Pansini F; Perkovic V; Manno C; Pellegrini F; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2009 Apr; (2):CD007784. PubMed ID: 19370693
[TBL] [Abstract][Full Text] [Related]
29. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues.
Campese VM; Ku E; Bigazzi R; Bianchi S
J Nephrol; 2011; 24(5):550-3. PubMed ID: 21887675
[TBL] [Abstract][Full Text] [Related]
30. HMG-CoA reductase inhibitors in chronic kidney disease.
Olyaei A; Steffl JL; MacLaughlan J; Trabolsi M; Quadri SP; Abbasi I; Lerma E
Am J Cardiovasc Drugs; 2013 Dec; 13(6):385-98. PubMed ID: 23975627
[TBL] [Abstract][Full Text] [Related]
31. [Stroke prevention by statins].
Sawada N; Itoh H; Nakao K
Nihon Rinsho; 2002 May; 60(5):993-1001. PubMed ID: 12030004
[TBL] [Abstract][Full Text] [Related]
32. Stage of chronic kidney disease and severity of coronary heart disease manifestation.
Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
Expert Opin Pharmacother; 2012 Mar; 13(4):457-60. PubMed ID: 22332967
[TBL] [Abstract][Full Text] [Related]
33. Statins: balancing benefits, efficacy and safety.
Clearfield MB
Expert Opin Pharmacother; 2002 May; 3(5):469-77. PubMed ID: 11996626
[TBL] [Abstract][Full Text] [Related]
34. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Maroo BP; Lavie CJ; Milani RV
Drugs Aging; 2008; 25(8):649-64. PubMed ID: 18665658
[TBL] [Abstract][Full Text] [Related]
35. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
Tzefos M; Olin JL
J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
[TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy of dyslipidemia.
McKenney JM
Cardiovasc Drugs Ther; 2001 Sep; 15(5):413-22. PubMed ID: 11855660
[TBL] [Abstract][Full Text] [Related]
37. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
38. Current and future treatment of hyperlipidemia: the role of statins.
Farnier M; Davignon J
Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
[TBL] [Abstract][Full Text] [Related]
39. Risks and benefits of continued aggressive statin therapy.
Gotto AM
Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III3-12. PubMed ID: 12708633
[TBL] [Abstract][Full Text] [Related]
40. [Clinical feature and treatment of the hyperlipidemia in the elderly].
Ito H
Nihon Rinsho; 2001 Mar; 59 Suppl 3():758-65. PubMed ID: 11347169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
